Pretty hefty dilution, ~18% of share count. I guess that's the price for internal commercialization.
You may be new to the biotech sector but its a fact of life that you raise $$$ when you can---not when you want to. This is smart strategy for HPTX.
only down -2% on 18% dilution with an implied mkt cap north of $400MM (fully diluted) with no revenues and the drug who ravicti is replacing has total sales of $15mm. I must be missing something here.